These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 38383148)
21. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Rossini M; Viapiana O; Gatti D; Adami S Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399 [TBL] [Abstract][Full Text] [Related]
22. Early onset acute tubular necrosis following single infusion of zoledronate. Yachoui R Clin Cases Miner Bone Metab; 2016; 13(2):154-156. PubMed ID: 27920815 [TBL] [Abstract][Full Text] [Related]
26. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Gonnelli S; Caffarelli C; Tanzilli L; Pondrelli C; Lucani B; Franci BM; Nuti R Bone; 2014 Apr; 61():27-32. PubMed ID: 24389416 [TBL] [Abstract][Full Text] [Related]
27. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978 [TBL] [Abstract][Full Text] [Related]
28. Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate. Morinishi T; Nawata A; Konishi R; Ono E; Takaori K; Maeda S CEN Case Rep; 2022 Feb; 11(1):120-125. PubMed ID: 34455572 [TBL] [Abstract][Full Text] [Related]
29. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667 [TBL] [Abstract][Full Text] [Related]
30. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Frampton JE; Perry CM Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic characteristics, pathology, and prognosis of 77 dogs with focal segmental glomerulosclerosis. Lorbach SK; Hokamp JA; Quimby JM; Cianciolo RE J Vet Intern Med; 2020 Sep; 34(5):1948-1956. PubMed ID: 33463760 [TBL] [Abstract][Full Text] [Related]
32. [Focal segmental glomerulosclerosis presenting nephrotic syndrome and acute renal failure in a patient with rheumatoid arthritis]. Sugiyama T; Sueishi M; Matsumura R; Tomioka H; Akikusa B Nihon Jinzo Gakkai Shi; 1997 May; 39(4):426-30. PubMed ID: 9198366 [TBL] [Abstract][Full Text] [Related]
33. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates. Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666 [TBL] [Abstract][Full Text] [Related]
34. Ibandronate: a new oral bisphosphonate for postmenopausal osteoporosis. Guay DR Consult Pharm; 2005 Dec; 20(12):1036-55. PubMed ID: 16548678 [TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of a patient with Kimura's disease associated with nephrotic syndrome and lymphadenopathy of the epitrochlear nodes. Zhu SL; Wei PF; Chen JH; Zhao ZF; Xu QN; Ye L BMC Nephrol; 2015 Feb; 16():10. PubMed ID: 25886601 [TBL] [Abstract][Full Text] [Related]
36. Nephrotic syndrome due to focal segmental glomerulosclerosis complicating scleroderma: a case report. Mehdipour Dalivand M; Hadjiabbasi A; Ramezanzadeh E; Habibzadeh SM; Goudarzi K; Shahriarirad R; Zayeni H J Med Case Rep; 2024 Jan; 18(1):32. PubMed ID: 38225664 [TBL] [Abstract][Full Text] [Related]
38. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Segarra A; Vila J; Pou L; Majó J; Arbós A; Quiles T; Piera LL Nephrol Dial Transplant; 2002 Apr; 17(4):655-62. PubMed ID: 11917061 [TBL] [Abstract][Full Text] [Related]
39. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study. Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y Bone; 2022 Sep; 162():116480. PubMed ID: 35787482 [TBL] [Abstract][Full Text] [Related]
40. Ibandronate: new options in the treatment of osteoporosis. Adami S; Viapiana O Drugs Today (Barc); 2003 Nov; 39(11):877-86. PubMed ID: 14702133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]